Skip to main navigation
Clene Inc. Clene Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Science
    • About CNM-Au8®
  • Pipeline
  • Patients
    • EAP
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • News
      • Events
    • Presentations
      • Investor Presentation
      • Scientific Posters & Presentations
      • Webinars
      • Publications
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Governance Documents
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
  • Contact
Clene Inc. Clene Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Science
    • About CNM-Au8®
  • Pipeline
  • Patients
    • EAP
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • News
      • Events
    • Presentations
      • Investor Presentation
      • Scientific Posters & Presentations
      • Webinars
      • Publications
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Governance Documents
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
  • Contact

News

Clene rockets on positive data for CNM-Au8 in ALS
July 15, 2022
True test for Clene’s ALS survival comes next
July 14, 2022
Tech Nation Radio Podcast: Episode 22-28 The Science: Feelings before Knowledge
July 8, 2022
A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs
July 8, 2022
CNM-Au8 Extends Survival, RESCUE-ALS Study Suggests
June 9, 2022
BioWorld Insider Podcast: New Therapies Vie to Change Fatal Course of Amyotrophic Lateral Sclerosis
June 3, 2022
Finding Genius Podcast: Restoring And Protecting Neurological Function Using Revolutionary Treatments
June 2, 2022
VIDEO: Survival improved among ALS patients treated with nanocrystal gold
April 13, 2022
Nanocrystalline Gold Treatment Slows Clinical Decline in Amyotrophic Lateral Sclerosis
April 8, 2022
Nanoparticle Shows Promise for ALS
April 7, 2022

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Next page next ›
  • Last page last »


1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2023 Clene Nanomedicine, Inc. - All rights reserved